Precise radiation, better airway preservation: vocal cord-only image-guided intensity-modulated radiation therapy for early-stage glottic cancer - Takeaways - MDSpire

Precise radiation, better airway preservation: vocal cord-only image-guided intensity-modulated radiation therapy for early-stage glottic cancer

  • By

  • Issa Mohamad

  • Ibrahim Alotain

  • Shatha Abu Taha

  • Mohammad Mukahal

  • Ayat Taqash

  • Mohammad Alsmairat

  • Abdulla Alzibdeh

  • Mohammad Berawi

  • Lina Wahbeh

  • Renda AlHabib

  • Akram Al-Ibraheem

  • Hikmat Abdel-Razeq

  • Fawzi Abuhijla

  • Ramiz Abu-Hijlih

  • Omar Al Saraireh

  • Ali Hosni

  • May 20, 2026

  • 0 min

Share

  • 1

    Vocal cord-only radiotherapy (VC-RT) significantly reduces tracheostomy rates compared to whole-larynx radiotherapy (WLRT) in early-stage glottic cancer patients.

  • 2

    In a study of 247 patients, 14.2% of those receiving WLRT required tracheostomy due to edema, while none in the VC-RT group experienced this complication.

  • 3

    The 3-year local failure rates were similar between VC-RT (7.6%) and WLRT (11.6%), indicating comparable oncologic outcomes.

  • 4

    Overall survival rates were also similar, with VC-RT at 93.3% and WLRT at 89.5%, suggesting effective cancer control with VC-RT.

  • 5

    VC-RT offers a promising alternative for treating early-stage glottic cancer, enhancing airway preservation without compromising treatment efficacy.

Original Source(s)

Precise radiation, better airway preservation: vocal cord-only image-guided intensity-modulated radiation therapy for early-stage glottic cancer

  • by Issa Mohamad, Ibrahim Alotain, Shatha Abu Taha, Mohammad Mukahal, Ayat Taqash, Mohammad Alsmairat, Abdulla Alzibdeh, Mohammad Berawi, Lina Wahbeh, Renda AlHabib, Akram Al-Ibraheem, Hikmat Abdel-Razeq, Fawzi Abuhijla, Ramiz Abu-Hijlih, Omar Al Saraireh, Ali Hosni

  • May 20, 2026

Related Content

Case Report: First description of an intracranial “NET” in ROHHAD syndrome; time to rename to the ROHHAD-NeCT syndrome?

Synthetic short RNA in cancer

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases